{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:23:09Z","timestamp":1781583789434,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The phase 3 randomized PERSIST study demonstrated the efficacy and tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for prevention of episodic migraines. We present findings from the open-label extension (OLE) of PERSIST, which evaluated the long-term efficacy and safety of galcanezumab in patients from China, India, and Russia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients completing the 3-month double-blind period of PERSIST were eligible for the 3-month OLE. Patients previously randomized to galcanezumab (GMB\/GMB group) continued to receive galcanezumab 120\u00a0mg at all three visits during the OLE whereas patients randomized to placebo received a 240\u00a0mg loading dose of galcanezumab and then two 120\u00a0mg doses (PBO\/GMB group). The primary outcome was the mean change (from double-blind baseline) in the number of monthly migraine headache days (MHDs) to month 6. Other endpoints included percent reduction in monthly MHDs from double-blind baseline to month 6, functional outcomes, safety and tolerability.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 99% of patients completing the double-blind period entered the OLE, and 96% completed through month 6. Patients in the GMB\/GMB group achieved continued improvements in efficacy, with the reduction from baseline in the mean number of monthly MHDs, and slightly increasing from 4.01\u00a0days at the end of the double-blind period to 4.62 at the end of the OLE. Of patients who were\u2009\u2265\u200950% responders to galcanezumab at month 3, 66% maintained this response through to month 6. Patients in the PBO\/GMB group experienced a rapid reduction in the number of monthly MHDs after initiation of galcanezumab, with a mean reduction from baseline of 4.56\u00a0days by month 6. The long-term benefits of galcanezumab were also supported by improvements in other efficacy and functional endpoints. All safety findings were consistent with the known long-term safety profile of galcanezumab; no patients experienced a treatment-related serious adverse event.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Galcanezumab was efficacious and well-tolerated in patients with episodic migraine from China, India and Russia, for up to 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrisABSTRACT_pals.gov NCT03963232, registered May 24, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01613-1","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T08:02:22Z","timestamp":1691136142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianmei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debashish","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirill","family":"Skorobogatykh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guogang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"2","key":"1613_CR1","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163(2):e293\u2013e309","journal-title":"Pain"},{"key":"1613_CR2","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 2018. 17(11): p. 954\u2013976.","DOI":"10.1016\/S1474-4422(18)30322-3"},{"issue":"5","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68(5):343\u2013349","journal-title":"Neurology"},{"issue":"1","key":"1613_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z et al (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19(1):10","journal-title":"J Headache Pain"},{"issue":"1","key":"1613_CR5","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20(1):22\u201333","journal-title":"J Manag Care Pharm"},{"issue":"8","key":"1613_CR6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1526-4610.2011.01985.x","volume":"51","author":"P Rizzoli","year":"2011","unstructured":"Rizzoli P, Loder EW (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache 51(8):1323\u20131335","journal-title":"Headache"},{"issue":"3","key":"1613_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villal\u00f3n","year":"2009","unstructured":"Villal\u00f3n CM, Olesen J (2009) The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther 124(3):309\u2013323","journal-title":"Pharmacol Ther"},{"issue":"8","key":"1613_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40263-021-00834-9","volume":"35","author":"LH Overeem","year":"2021","unstructured":"Overeem LH et al (2021) Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. CNS Drugs 35(8):805\u2013820","journal-title":"CNS Drugs"},{"issue":"7","key":"1613_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K et al (2021) Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851\u2013864","journal-title":"Cephalalgia"},{"issue":"9","key":"1613_CR10","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL et al (2018) Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"8","key":"1613_CR11","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442\u20131454","journal-title":"Cephalalgia"},{"issue":"24","key":"1613_CR12","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC et al (2018) Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"5","key":"1613_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","volume":"38","author":"P Pozo-Rosich","year":"2022","unstructured":"Pozo-Rosich P et al (2022) Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin 38(5):731\u2013742","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"1613_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814\u2013825","journal-title":"Lancet Neurol"},{"issue":"11","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U et al (2021) Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Adv Ther 38(11):5465\u20135483","journal-title":"Adv Ther"},{"issue":"1","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-022-01458-0","volume":"23","author":"B Hu","year":"2022","unstructured":"Hu B et al (2022) Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 23(1):90","journal-title":"J Headache Pain"},{"key":"1613_CR17","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 2018. 38(1): p. 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1613_CR18","unstructured":"Speck, R., et al. The Migraine-Specific Quality of Life Questionnaire, Role Function Restrictive Domain: Defining Clinically Meaningful Categories of Functional Impairment Severity. in JOURNAL OF HEADACHE AND PAIN 2021, 22(Supp 1): P0226. BMC CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND."},{"key":"1613_CR19","unstructured":"W, G., ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch. 1976: p. 217\u201322."},{"issue":"9","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB et al (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9):854\u2013861","journal-title":"Headache"},{"issue":"5","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"issue":"18","key":"1613_CR22","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ et al (2020) Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology 95(18):e2487\u2013e2499","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01613-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:01:53Z","timestamp":1700510513000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01613-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01613-1","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical Guidelines, International Conference on Harmonisation guidelines for Good Clinical Practice, and applicable local laws and regulations. Patients provided written informed consent before undergoing any study procedures. The appropriate institutional review board for each participating site approved the study protocol, patient consent form and other relevant documents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LS, HL and CQ are full-time employees of Eli Lily and Company. SY serves as associated editor of the Journal of Headache and Pain and as a member of the International Headache Society. MZ has no competing interests. JZ, LZ, DC, KS, GL, XY and SY declare receiving clinical research fees from Eli Lilly and Company for participating as investigators in the PERSIST study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}